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diseases and travellers without rheumatic diseases (controls). Participants who travelled internation-
ally received questionnaires 1 and 13 weeks post-travel. We compared travel patterns, risk behaviours,
and travel-associated problems during and after the trips in both groups. RESULTS 274 participants
returned post-travel questionnaires (65 rheumatic patients, 209 controls). Controls more frequently trav-
elled to subtropical/tropical destinations and stayed longer abroad. 64% of all participants experienced
health problems during travel (74% rheumatic patients vs. 62% controls, P = 0.11). Pre-travel, pa-
tients reported a higher susceptibility to gastrointestinal infections. During travel, a higher percentage
of rheumatic patients cancelled the day programme due to health problems (13% vs. 4%, P = 0.024).
The main problems in rheumatic patients occurred due to the underlying rheumatic diseases, or were
of psychological nature. Although not statistically significant, infectious disease symptoms (rhinitis,
cough) occurred more frequently in controls. When only considering subtropical/tropical destinations,
rheumatic patients more frequently had gastrointestinal problems during travel - and skin infections after
the trip. CONCLUSIONS This study does not support the notion that patients with rheumatic diseases
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Background: Patients with chronic conditions travel around theworld more than ever. Only few 
studies have examined travel patterns and health outcomes of patients with rheumatic diseases during 
international travel. 
 
Method: We conducted a multi-centre prospective cohort study in Switzerland, in which we studied 
the immunogenicity and safety of vaccinations in patients with rheumatic diseases and travellers 
without rheumatic diseases (controls). Participants who travelled internationally received 
questionnaires 1 and 13 weeks post-travel. We compared travel patterns, risk behaviours, and travel-
associated problems during and after the trips in both groups. 
 
Results: 274 participants returned post-travel questionnaires (65 rheumatic patients, 209 controls). 
Controls more frequently travelled to subtropical/tropical destinations and stayed longer abroad. 64% 
of all participants experienced health problems during travel (74% rheumatic patients v . 62% controls, 
P=0.11). Pre-travel, patients reported a higher susceptibility to gastrointestinal infections. 
During travel, a higher percentage of rheumatic patients cancelled the day programme due to health 
problems (13% vs. 4%, P=0.024). The main problems in rheumatic patients occurred due to the 
underlying rheumatic diseases, or were of psychological nature. Although not statistically significant, 
infectious disease symptoms (rhinitis, cough) occurred more frequently in controls. When only 
considering subtropical/tropical destinations, rheumatic patients more frequently had gastrointestinal 
problems during travel - and skin infections after the trip.  
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Conclusions: This study does not support the notion that patients with rheumatic diseases should 
avoid international travel for an increased risk of infections. In patients with subtropical/tropical 







International tourism grew by 4% between January-September 2019 according to the World Tourism 
Organization (UNWTO) compared to the same period in the previous year and further increases might 
be expected[1]. As new medical care and treatment options have been developed over the past 
decades for patients suffering from rheumatic disorers, these patients feel healthier and often lead a 
life-style comparable to that of healthy persons. A a consequence, international travel has also 
increased in this patient group[2,3].  
 
Only few investigators have assessed health risks related to travel in tropical countries in rheumatic 
disease patients. Wieten et al. examined the health risks of a heterogeneous group of 
immunocompromised travellers. The data suggest that travellers with underlying conditions were at an 
increased risk for travel related diseases, especially for gastrointestinal symptoms[4]. Baaten et al. 
examined whether or not travellers on immunosuppressant  with various underlying diseases had a 
higher incidence of health problems during international travel than healthy travellers. The authors 
found skin infections more often in immunosuppressed travellers than in controls[5]. No other 
symptomatic infections appeared more frequently in immunosuppressed compared to non-
immunocompromised travellers.  
 
In recent years, persons with rheumatic diseases have constituted a large proportion of 
immunocompromised travellers[6]. They have an increased risk of infection, partly because of the 
underlying conditions per se, and partly due to taken immunosuppressive medications[7–10]. The risk 
for influenza infection[11,12], pneumococcal pneumonia[13], primary varicella infection[14] and 
herpes zoster[15] is elevated in rheumatic patients compared to the general population.  
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An increased risk for specific diseases from subtropical or tropical countries, such as malaria, dengue 
and hepatitis A has not been described in the literature. Travel associated infections may have a more 
severe course in immunocompromised individuals, as demonstrated for tuberculosis on tumour 
necrosis factor alpha inhibitor therapy[2,16]. 
 
Although the vulnerability and exposure to health risks of travellers depends on the destination, 
duration and behavioural factors[17–19], little is known about rheumatic disease patients´ travel 
destinations and behaviour, their incident health problems and evolution of disease activity. 
 
In the context of a prospective vaccination study in patients with rheumatic diseases and travellers 
without rheumatic diseases (controls) we sent post-travel questionnaires to those with an international 
trip with the aim of comparing travel patterns, risk behaviours, travel-associated problems and needs 
in patients with rheumatic diseases and controls. Furthermore, we studied the effects of travel on 






2.1. Study design  
 
This study investigating travel issues was nested within a multi-centre prospective cohort study 
(ClinicalTrials.gov Identifier: NCT01947465) in 6 rheumatology and 2 travel clinics in Switzerland. 
In that particular study the immunogenicity and safety of a hepatitis A and/or tetanus/diphtheria 
booster vaccination was prospectively studied (details on study design and recruitment described in 
[20]). Control participants (individuals without rheumatic diseases) were recruited in the travel clinics, 
patients with rheumatic diseases were recruited in travel clinics and rheumatology clinics, with a 
preponderance being enrolled in the rheumatology clinics. 
Participants were recruited between January 2014 and December 2015. We sent out the travel 
questionnaires to participants of the vaccination study who travelled internationally (1week and 13 
weeks after their return). A prepaid return envelope was included. The 1-week post-travel 
questionnaire contained questions on the following domains: a) travel patterns (destinations, length of 
stay, travel style, place of stay, activities during the trip), b) risk behaviours (food hygiene, protection 
from mosquito bites, contact with animals), c) travel associated health problems (e.g. fever, 
gastrointestinal problems, respiratory infections, skin infections, urinary tract infections, accidents), d) 
rheumatic disease activity: worsening or improvement of disease symptoms (e.g. arthralgia, joint 
swelling), e) travel-associated incidents (requirement of medical assistance, change of original travel 
plans due to health issues). The 1-week questionnaire comprised questions on risk behaviours and 
health problems during the trip and health problems that occurred up to 1 week after the return. It also 
included a section on the participants’ own perception regarding their vulnerability to infections and 
other health problems before the trip. They were asked to rate their vulnerability on a scale from 1 
(hardly susceptible) to 5 (very susceptible). 
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In the 13-week post-travel questionnaire we assessed wh ther or not the health problems and medical 
needs differed between patients with rheumatic diseases and controls during the 13 weeks after their 
return from the trip. 
 
2.2. Study population  
 
Rheumatic patients were recruited consecutively into the study if they had one of the following 
underlying conditions: rheumatoid arthritis (RA), axial spondyloarthritis (SpA), peripheral psoriatic 
arthritis (PsA), or vasculitis (Behçet's disease or ANCA-associated vasculitis). All participants were 
aged 18 years and above. If patients took one of the following medications in the respective time 
period they were classified as immunosuppressed:  systemic corticosteroids, methotrexate, or 
etanercept within the past month; azathioprine within the past two months; other conventional 
synthetic disease modifying anti-rheumatic drugs (csDMARDs), adalimumab, certolizumab, 
golimumab, infliximab, and other biological DMARDs within the past three months; leflunomide 
within the past six months; and rituximab in the past 12 months [21,22]. 
The study was approved by the Aargau-Solothurn, Bern, Geneva, Nordwestschweiz, St. Gallen and 
Zurich Ethics committees (Reference numbers EK Aargau-Solothurn: 2013/062, Bern: 182/13, CCER 
2016-00218, EKNZ 257/13, EKSG 13/138, KEK-ZH 2013-0188). All participants signed an informed 




The analysis was executed with Stata 14.0 (Stata Corp. LP, Texas, USA). For evaluation of 
differences in proportions we used a chi-squared or Fisher’s exact test, as appropriate. The Wilcoxon 





3.1. Travellers’ demographics  
 
Participants travelled between January 2014 and May 2016. Overall, 654 participants were enrolled in 
the vaccination study (349 with rheumatic diseases and 305 controls). 274 (42%) participants returned 
a completed post-travel questionnaire; 189 completed both the 1-week and the 13-weeks post-travel 
questionnaires, 58 persons only the first questionnaire and 27 only the second. 65 (19%) travellers 
with rheumatic diseases returned a questionnaire and 209 (67%) travellers without rheumatic diseases 
sent the completed questionnaire back. Sex and age did not differ between the group who returned a 
post-travel questionnaire and the one who did not. The baseline disease activity score did not differ n 
patients with rheumatoid arthritis or peripheral psoriasis who returned a post-travel questionnaire and 
those who did not. Participants with spondyloarthritis who returned the post-travel questionnaires had 
lower disease activity scores on a median than those who did not return the questionnaires (Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI) 2.45 vs. 4.40). 
 
Travellers with rheumatic conditions had rheumatoid arthritis (n=28, 43%), spondyloarthritis (n=19, 
30%), vasculitis (n=8, 12%), and peripheral psoriatic arthritis (n=10, 15%). The majority of 
participants (n=56, 86%) received immunosuppressive drugs at the time of travel. 14 were on 
corticosteroid treatment, 24 had conventional DMARDs (cDMARDs). 23 were treated with tumour 
necrosis factor alpha inhibitors, and 14 received other biological disease modifying anti-rheumatic 
drugs (bDMARD). 
 
Travellers with rheumatic diseases were more often female than travellers without rheumatic diseases 
(68% vs. 54%, P=0.052). The median age was comparable between participants with and without 
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rheumatic conditions (48.5 years, IQR 34.6-57.3 vs. 48.9, IQR 31.7-61.0, P=0.89, Table 1). Patients 
also more often had other chronic medical conditions than the controls (51% vs. 27%, P<0.001).  
 
3.2. Travel reasons and destinations 
 
While 96% of journeys led to subtropical/tropical are s in controls, only 59% of destinations in 
travellers with rheumatic diseases were subtropical/tropical. Among patients on immunosuppressive 
therapies, 22 (45%) undertook a trip to a subtropical/tropical country. The remaining trips led to 
Europe or North America (Table 1). More than 80% of trips were undertaken for touristic reasons in 
both groups. Controls stayed longer abroad than rheumatic patients (18 days, IQR 14-24 vs. 14 days, 
IQR 8-24, P=0.0074, Table 1). 
 
3.3. Travel style 
 
Controls often travelled more luxuriously than rheumatic patients (30% vs. 23%, P=0.37, Table 1). 
Rheumatic patients noted “by foot” as their main mode f transport more often than controls (28% vs. 
7%, P<0.001). The results did not change when we compared immunosuppressed and non-
immunosuppressed travellers (non-immunosuppressed containing not-immunosuppressed patients and 
controls).  
 More than 50% of all travellers stayed at a beach during their travels and a similar percentage visited 
cities and cultural sites. Slightly more controls than rheumatic patients undertook trekking activities 
(18% vs. 14%, P=0.46). Compared to rheumatic patients, trekking in controls often included great 
physical efforts (48% vs. 38%, P=0.58), altitude differences of more than 1,000m (52% vs. 29%, 
P=0.27) and longer durations (53% vs. 38%, P=0.43). Around 5% in both groups stayed in areas 
where time to medical access would have taken more than 24 hours (Table 1). 
 
 11
3.4. Risk behaviour  
 
Nearly 35% of all subjects reported a contact with warm-blooded animals (Table 1). While no 
rheumatic patients were bitten or scratched nor had open wounds licked by mammals, 6 control 
subjects reported such an incident.  Apart from controls drinking more beer, no difference in drinking 
behaviour/hygiene concerning beverages was noted, also when only travellers with 
subtropical/tropical destinations were looked at (Table 2).  
Regarding food hygiene, patients with rheumatic diseases demonstrated a more cautious behaviour 
than the control group. They ate less often at food stands (16% vs. 28%, P=0.064), ate raw fish less 
often (10% vs. 21%, P=0.076), ate fruit that they had not peeled themselves less frequently (35% vs.
57%, P=0.003), and less salads prepared by others (57%vs. 70%, P=0.067).  
When comparing eating behaviour only in those participants travelling to subtropical/tropical 
countries, more patients ate raw meat and self-prepared salads (Table 2).  
More controls than patients used mosquito protection during the day, evening and night. The 
difference became less distinct when comparing only those travelling to subtropical/tropical 
destinations (day, 86% vs. 76%, P=0.13; night, 77% vs. 70%, P=0.41, Table 2). 
Controls and patients obtained travel health insurance and insurance including repatriation for the trip 
with equal frequency (around 50%, Table 1).  
A travel pharmacy, including antibiotics and alkaline soap, was carried by one fifth of patients and 
controls (17% and 19%). Controls were more likely to carry sunscreen with them (94% vs. 74%, 
P<0.001). The difference stayed noteworthy when comparing only those travelling to 
subtropical/tropical destinations (92% vs. 77%, P=0.044).  
 
3.5. Health problems before the trip  
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Regarding the vulnerability to airway infections, urinary tract infections, skin lesions and skin 
infections in Switzerland, no differences between rheumatic disease patients and controls were 
reported. However, patients reported a higher susceptibility to gastrointestinal infections prior to 
travel (P=0.01 data not shown, questionnaire on health problems in supplementary).  
 
3.6. Health problems during the trip 
  
Overall, 64% of travellers reported health problems during their trip. Slightly more rheumatic disease 
patients than controls had health issues during the trip (74% vs. 62%, P=0.11, Figure 1 (A)).  
When only looking at health problems in travellers to subtropical/tropical destinations, 87% of 
rheumatic patients and 62% of controls experienced h alth problems (P=0.006, Figure 1 (B)). 
Nightmares were experienced by 19% of patients and 8% of controls (P=0.047). Rheumatic disease 
patients felt fatigued considerably more often (43% vs. 16%), tense (21% vs. 4%) and depressed (28% 
vs. 4%) than controls (all P<0.001). Patients and controls reported gastrointestinal problems with the 
same frequency (31% and 30%, P=0.87) when looking at all destinations. In the participants travelling 
only to subtropical/tropical destinations, 52% of rheumatic patients and 32% of controls had 
gastrointestinal problems (P=0.03, Figure 2 (B)). Skin infections were reported to a similar extent in 
both groups (overall: rheumatic 9%, controls 8%, P=0.74; subtropical/tropical: rheumatic 11%, 
controls 8%, P=0.61).  
Overall, more controls had cough (18% vs. 12%, P=0.35). More patients than controls used antibiotics 
(10% vs. 6%, P=0.15) and medications against fever/pain (49% vs. 29%, P<0.001) during the trip. 
Only controls used anti-malarials for self-treatment (3%); none of the patients did. 
 
Nearly 9% of all participants experienced an accident during the trip (n=22, controls: 17, patients: 5). 
Of these, 43% had an accident as a pedestrian (n=9); controls more often than patients (50% (n=8/17) 
vs. 20% (n=1/5)); 14% had a sports injury (6% (n=1/17) vs. 40% (n=2/5)), 10% had a motorbike 
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accident (6% (n=1/17) vs. 20% (n=1/5)) and 33% had an accident during a different activity (38% 
(n=6/17) vs. 20% (n=1/5)) (data not shown). The findings did not change when comparing 
immunosuppressed patients to all other travellers. During the trip quantitatively more 
immunosuppressed patients reported a health problem (75 % vs. 62%, P=0.11). We did not detect 
more infectious diseases in the immunosuppressed when we compared this group with all other 
travellers. 
 
3.7. Travel plan changes due to health problems 
 
More rheumatic patients had to cancel the planned day programme (e.g. visit to a museum, city tour) 
due to health problems than controls (13% vs. 4%, P=0.024). In 50%, the underlying rheumatic 
disease caused the disruption. Rheumatic patients more often had to restrict the time spent with 
planned activities due to health problems (25% vs. 5%, P<0.001) and it was more strenuous for 
rheumatic patients to follow the planned daily activities (21% vs. 3%, P<0.001, Table 1). 
 
3.8. Health problems in the first week after the trip  
 
In the first week after the trip rheumatic disease patients reported drastically more health problems 
than controls (54% vs. 33% P=0.006, Figure 1 (A)). A similar picture was seen when only those 
participants travelling to subtropical/tropical destinations were looked at (63% vs. 33%, P=0.002, 
Figure 1 (B)). Overall, patients experienced more sleep problems than controls (29% vs. 15%, 
P=0.095), they also felt more often fatigued (52% vs. 29%, P= 0.033), tense (25% vs. 7%, P=0.013) 
and depressed (22% vs. 8%, P=0.062).  
The frequency of gastrointestinal problems, fever and cough decreased in the first week after travel in 
both groups. Patients still slightly more frequently reported gastrointestinal symptoms (all 
destinations: 11% vs. 10%, P=0.87, subtropical/tropical destinations: 18% vs. 11%, P=0.26); controls 
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more often reported cough (16% vs. 13%, P=0.64) and the occurrence of fever was similarly 
distributed between both groups, irrespective if all or only subtropical/tropical countries were looked 
at (Figure 1 (A) and (B)).  One week after the trip, skin infections were reported more frequently in 
the rheumatic patient group than in controls (overall: rheumatic 6%, controls 0%, P=0.047; 
subtropical/tropical: rheumatic 5%, controls 0%, P=0.084).  
When comparing the number of health events only in the patients on immunosuppression to all other 
travellers one week after the trip the findings didnot change considerably (53% vs. 34%, P=0.015). 
Overall, we did not find more infectious diseases when comparing the immunosuppressed group with 
all other travellers. 
 
3.9. Health problems in the 13 weeks after the trip  
 
During the 13 weeks after the trip, again rheumatic patients reported more health problems than 
controls (59% vs. 37%, P=0.004, Figure 1 (A)). When comparing the frequency of overall health 
problems in patients and controls travelling to subtropical/tropical destinations in the 13 weeks after 
the trip, the difference becomes less distinct (48% vs. 38%, P=0.36). More rheumatic disease patients 
had gastrointestinal problems (all destinations: 17% vs. 6%, P=0.005, subtropical/tropical destinations 
18% vs. 6%, P=0.015). Overall, 2% of the controls reported skin infections compared to 15% of 
rheumatic patients (P=0.013; subtropical/tropical countries: 2% vs. 13%, P=0.060). Overall, rheumatic 
patients had more sleep problems than controls (30% vs. 12%, P=0.032). Fatigue (58% vs. 28%, 
P=0.005), tension (34% vs. 23%, P=0.24) and depression (25% vs. 14%, P=0.21) were also still more 
frequently reported by rheumatic patients than controls.  
Overall, controls reported more often coughs (31% vs. 21%, P=0.27), rhinitis (26% vs. 18%, P=0.41), 
a sore throat (20% vs. 12%, P=0.34), and fever (12% vs. 9%, P=0.69). 
Again, when comparing health problems 13 weeks after the trip only in the immunosuppressed to the 
other travellers, the results did not change notably: also more immunosuppressed patients reported a 
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health problem during this period (56% vs. 36%, P=0.02). We did not identify more infectious 
diseases in the immunosuppressed when comparing the immunosuppressed group with all other 
travellers. 
 
3.10. Physician consultations and hospitalisations 
 
During the trip, 4% of patients consulted a physician. This percentage increased to 16% in the first 
week and to 54% in the 13 weeks after the trip. Controls showed an increase of consultations from 3% 
during the trip, to 6% in the first week after the trip, and to 23% in the 13 weeks after the trip. 
During the trip, no participant had to be hospitalised. In the first week after the trip, two rheumatic 
patients and one control reported a hospital admission. Reasons in rheumatic patients were a bladder 
tumour and fever; the reason in the control was a hallux-valgus operation. 
In the 13 weeks after their travels six rheumatic disease patients and three controls were admitted to 
hospital. Reasons in rheumatic patients were bacteri l infections, a cataract operation, a hallux valgus 
operation, poisoning, monthly infliximab infusion ad a bladder tumour. The reasons in controls were 
a hallux valgus operation, a transitory ischaemic attack and a myocardial infarction.  
 
3.11. Complaints specific to rheumatic disease patients 
Median body pain before the trip in patients with rheumatic diseases was 1 (scale from 0-10, 0 being 
no pain, 10 worst imaginable pain, IQR 0-4) and during the trip it was reported to be 2 (IQR 0-4, 
P=0.44). In the 13 weeks after the trip median body pain was 2 (IQR 0-5, P=0.62). 
 
When asked about general musculoskeletal complaints, joint swelling and joint mobility, patients 
reported a slight worsening during the trip (Figure 2). In the first week after the trip a slight 
improvement of joint pain and joint mobility was noted compared to before the trip. 13 weeks after 
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the trip, all rheumatic symptoms (musculoskeletal symptoms, joint pain, joint swelling and joint 




Overall, psychological problems and not infections were the most frequently reported health problem 
in travellers with rheumatic diseases. Two thirds of all participants reported health problems during 
their travel. Infections were not a major issue fortravellers with rheumatic diseases – although 
patients with rheumatic diseases are known to suffer generally more frequently from infections [7–15] 
and despite travel vaccinations may be less immunoge ic in this often immunosuppressed group 
[23,24]. During (74 % vs. 62%) and after the trip more patients than controls eported a health 
problem (54% vs. 33% 1 week after the trip; 53% vs. 37% 13 weeks after the trip). The main problems 
in patients were of psychological nature or due to the underlying rheumatic disease. While fatigue was
the main symptom in rheumatic disease patients during and after the trip (followed by gastrointestinal 
problems and by feeling depressed), the most frequent health problems in controls were 
gastrointestinal problems (during the trip), fatigue, rhinitis (first week after the trip), and cough (13 
weeks after the trip).  
When we only looked at subtropical/tropical destinations, patients with rheumatic diseases reported 
more frequently gastrointestinal symptoms during andfter travel; skin infections were noted more 
often after the trip. A higher frequency of gastrointestinal problems and skin infections in travellers 
with rheumatic diseases to subtropical/tropical destinations than in controls makes our results 
comparable to the study results by Wieten et al. and Baaten et al. [4,5]. However, the patients in our 
study also reported a higher susceptibility to gastrointestinal infections than controls before travel. 
Thus it remains unclear to what extent the gastrointestinal problems were associated with the trip. 
A study from Farnham et al. showed that the most comm n symptoms during travel by tourists to 
Thailand were mental health problems (exhaustion 80%, mental distress 50%)[25]. Neuropsychiatric 
problems in travellers have already been reported in other studies. 11.3% of young Israeli (20-25y, 
healthy) travellers to the tropics reported psychological symptoms[26].  
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In our study, it is striking how psychological symptoms increased after the trip in rheumatic disease 
participants and still had a high prevalence 13 weeks after the trip (during a time period, which most 
probably depicts “normal life”). Although we cannot compare them to data before the trip (only to 
data after the trip), which is a clear limitation of this study, patients appeared to be psychologically f r 
better off whilst travelling. Interestingly, fatigue and tension also increased in the controls after 
travelling. It could mean that being away had a positive influence on these health aspects in both, 
patients and controls. The study by Farnham et al, did not gather pre-and post travel data on 
psychological well-being. Thus, it is unknown whether mental problems were worse before or after 
travel. Furthermore, generally young and healthy travellers were included in the study. These two 
aspects limit a direct comparability with our study. 
Every 10th traveller experienced an accident during the trip 
Injury is one of the main causes of morbidity and mortality among travellers[27–29]. More than 1.35 
million people die each year as victims of traffic a cidents and accidents are the leading cause of 
death for young adults and children aged 5 – 29 years[30]. Farnham et al. reported that 23% travellers 
in Thailand experienced an accident[25]; in our study, 10% of the participants reported an accident, 
which is still a considerable number. The difference could be explained by a large variety of travel 
destinations in our study. It has previously been shown that the risk of an accident for Swiss travellers 
is highest in Thailand[31]. In addition, our travellers were considerably older than in the Farnham 
study.  
Rheumatic symptoms worsened during the trip  
Although we did not examine the relation between musculoskeletal symptoms and specific 
destinations we found a worsening during the trip for rheumatic problems in general and in particular 
for arthritic swelling and stiffness. Symptoms could have been affected by weather conditions[32–34]. 
Studies from Hollander et al. and Patberg et al. reported that a weather change like rising humidity 
and falling barometric pressure produced a significant increase of arthritic pain, swelling and stiffness, 
but results are still inconclusive[34,35]. It has been shown that pre-existing diseases can cause the 
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main problems in elderly travellers while abroad [36]. Also, in our study we showed that the 
rheumatic disease itself often detained patients from their planned activities. 
Depending on the subject - sometimes patients and sometimes controls showed a riskier behaviour 
Risk behaviour in rheumatic patients did not show a cle r pattern, e.g. in some aspects food hygiene 
was more careful in patients and in other regards controls showed a more prudent behaviour. Patients 
behaved more carefully regarding mammal contact. However, controls used better mosquito 
protection and carried sunscreen in their travel pharmacy.  Considering that skin cancer is one of the 
most frequent malignancies in immunosuppressed patients[37–39], the latter is a worrying finding. 
Strengths and limitations of our study 
Travel destinations and travel duration differed between rheumatic patients and controls and thus 
some results may be inconclusive. One reason for difering travel destinations is that the controls were 
enrolled in the travel clinics and the majority of patients in the rheumatology clinics. However, we did 
not find major differences, when we compared risk behaviours only in travellers to 
subtropical/tropical destinations.  
Our study was conducted retrospectively: as participants answered the questionnaires after their trips 
the data may be confined by recall limitations in both groups.  
In our study we depict a real-world scenario of patients with rheumatic diseases and travellers without 
rheumatic diseases. We studied for the first time non-i fectious disease risks in travellers with 
rheumatic diseases and not only explored health outcomes, but also risk behaviour. However, 
participant numbers for rheumatic patients were low, and thus our results may not be generalisable.  
We performed a sub-analysis in those only travelling to subtropical/tropical destinations; here the 
participant numbers of patients with rheumatic diseases is even lower; due to the small number of 
participants with rheumatic diseases we only conducted descriptive analyses. To characterise 





Overall, no hospitalisation in rheumatic disease patients or controls occurred during the trip and no 
severe diseases were reported by any of the study partici nts. Although patients on 
immunosuppressants may be at a generally increased ri k of infection, this study (knowing its 
limitations) does not support the perception amongst many treating physicians and patients that 
individuals with rheumatic diseases should avoid inter ational travel for an increased risk of 
infections. However, patients may be at higher risk of gastrointestinal problems when travelling to 
subtropical/tropical countries and may report of more skin infections after travelling to these 
destinations. Apart from that, health problems in travellers with rheumatic diseases were particularly 
of psychological nature during and after travel or caused by underlying rheumatic diseases. Travelling 
can modify rheumatic symptoms and signs depending o weather conditions. In some aspects 
rheumatic patients showed a more careful behaviour while travelling, in some aspects a less careful 
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Figure 1 (A): Health problems in rheumatic disease patients and co trols during the trip, 1 week after 
the trip and 13 weeks after the trip – all destinations (in percentage) 
 
Figure 1 (B): Health problems in rheumatic disease patients and co trols during the trip, 1 week after 
the trip and 13 weeks after the trip - subtropical/tropical destinations (in percentage) 
 
Figure 2: Improvement or worsening of rheumatic symptoms during, 1 week and 13 weeks after the 
trip compared to before the trip (median). Positive numbers indicate an improvement, 0 means no 
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Figure 1 (B): Health problems in rheumatic disease patients and co trols during the trip, 1 week after 
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Figure 2: Improvement or worsening of rheumatic symptoms during, 1 week and 13 weeks after the 
trip compared to before the trip (median). Positive numbers indicate an improvement, 0 means no 
















symptoms Joint pain Joint swelling Joint mobility
During trip compared to before the trip
1 week after the trip compared to before the trip
13 weeks after the trip compared to before the trip
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Table 1: Baseline and travel characteristics  
 
all (274) 


















Nationality (Swiss) 215 (78.5) 50 (76.9) 165 (79.0) 0.99 
Other (non-rheumatic) chronic diseases**  90 (32.9) 33 (50.8) 57 (27.3) <0.001 
Destination ****  North America / Europe 57 (13.2) 44 (41.5) 13 (4.0) 
<0.001 Destinations outside 
Europe/North America 
374 (86.8) 62 (58.5) 312 (96.0) 
Top Five South Africa 30 
(7.0) 
Italy 8 (7.6) South Africa 28 (8.6) 
 
India 20 (4.6) Portugal 7 (6.6) India 18 (5.5) 
Thailand 20 (4.6) Spain 6 (5.7) Botswana 16 (4.9) 
Botswana 17 (3.9) Thailand 5 (4.7) Namibia 15 (4.6) 
Namibia 15 (3.5) Vietnam 4 (3.8) Thailand 15 (4.6) 
Top Five outside 
Europe/North America 
South Africa 30 
(7.0) 
Thailand 5 (4.7)   
India 20 (4.6) Vietnam 4 (3.8)   

























(each 2 (1.9)) 
 







































































Travel reason Tourism 188 (82.8) 37 (80.4) 151 (83.4) 
0.05 
Visiting friends and 
relatives 
16 (7.1) 6 (13.0) 10 (5.5) 
Business / aid project 13 (5.7) 0 13 (7.2) 
Other ***  10 (4.4) 3 (6.5) 7 (3.9) 
Travel style Backpacking/low budget 27 (11.1) 7 (12.3) 20 (10.7) 
0.01 
Middle class 109 (44.7) 24 (42.1) 85 (45.5) 
Luxury 69 (28.3) 13 (22.8) 56 (30.0) 
Other 39 (16.0) 13 (22.8) 26 (13.9) 
Trip Duration (days) 
 
18 (14-24) 14 (8-24) 18 (14-24) 0.0074 
Accommodation Hotel 160 (64.8) 31 (53.5) 129 (68.3) 0.039 
Youth hostel/low 
budget/guest house 
41 (16.6) 9 (15.5) 32 (16.9) 0.80 
Apartment 18 (7.3) 12 (20.7) 6 (3.2) <0.001 
Local friends/family 25 (10.1) 6 (10.3) 19 (10.1) 0.95 
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European friends/family 12 (4.9) 3 ( 5.2) 9 (4.8) 0.90 
Other accommodation 35 (14.2) 7 (12.1) 28 (14.8) 0.60 
Medical access Stayed in areas with time 
to medical access >24h 
12 (4.9) 3 (5.2) 9 (4.8) 0.91 
Contact to mammals/warm-blooded animals 85 (34.7) 23 (39.7) 62 (33.2) 0.36 
Travel insurance / 
pharmacy 
Travel health insurance 111 (50.9) 28 (53.9) 83 (50.0) 0.63 
Skin repellent  197 (82.8) 27 (49.1) 170 (92.9) <0.001 
Insecticide (clothes) 115 (50.9) 16 (30.2) 99 (57.2) 0.001 
Sun screen 210 (89.4) 37 (74.0) 173 (93.5) <0.001 
Travel plan change due to health problems  
Cancelled day programme 15 (6.2) 7 (12.5) 8 (4.3) 0.024 
Spent less time on daily programme 24 (9.8) 14 (24.6) 10 (5.3) <0.001 
Strenuous to follow daily programme 17 (7.0) 12 (21.4) 5 (2.7) <0.001 
Shortened trip due to health problems 2 (0.8) 1 (1.8) 1 (0.5) 0.37 
* rheumatoid arthritis n=28, spondyloarthritis n=19, vasculitis n=8, peripheral psoariasis n=10, (immunosuppressed n=56) 
** chronic diseases included cancer (breast, cervix, prostate, other), diabetes, chronic hepatitis, lung diseases, kidney 
diseases, cardiovascular diseases, neurological disease , psychological diseases and other diseases 
*** other reasons included religious trips (e.g. pilgrimage), internships, studying abroad 






Table 2: Risk factors, risk behaviour and precautions in patients with rheumatic diseases and controls 
with subtropical/tropical destinations 
 
 all (220) 






Drinks during trip Can/Bottle 165 (75.0) 27 (81.8) 138 (73.8) 0.32 
Water 195 (88.6) 29 (87.9) 166 (88.8) 0.88 
Tap water 44 (20.0) 4 (12.1) 40 (21.4) 0.22 
Milk (unknown if pasteurized) 66 (30.0) 10 (30.3) 56 (30.0) 0.97 
Fruit juice with ice 92 (41.8) 15 (45.5) 77 (41.2) 0.65 
Beer 142 (64.6) 16 (48.5) 126 (67.4) 0.04 
Wine 144 (65.5) 19 (57.6) 125 (66.8) 0.30 
Long drink with ice 113 (51.4) 20 (60.6) 93 (49.7) 0.35 
Long drink without ice 33 (15.0) 4 (12.1) 29 (15.5) 0.62 
Food / hygiene during 
trip  
Food stand 61 (27.7) 9 (27.3) 52 (27.8) 0.95 
Raw fish 45 (20.5) 6 (18.2) 39 (20.9) 0.73 
Seafood 73 (33.2) 11 (33.3) 62 (33.2) 0.98 
Raw meat 11 (5.0) 4 (12.1) 7 (3.7) 0.04 
Fruits with skin 89 (40.5) 13 (39.4) 76 (40.6) 0.89 
Fruits not peeled by oneself 122 (55.5) 14 (42.4) 108 (57.8) 0.10 
Salad self-prepared 31 (14.1) 9 (27.3) 22 (11.8) 0.02 
Salad not self-prepared 150 (68.2) 20 (60.6) 130 (69.5) 0.31 
Raw vegetables  121 (55.0) 21 (63.6) 100 (53.5) 0.28 
Hot food on the plane 194 (88.2) 29 (87.9) 165 (88.2) 0.95 
Raw food on the plane 127 (57.7) 22 (66.7) 105 (56.2) 0.26 
Washing / disinfecting hands 
regularly before eating 
145 (66.5) 24 (72.7) 121 (65.4) 0.56 
Mosquito protection Mosquito protection day / evening 186 (84.6) 25 (75.8) 161 (86.1) 0.13 
Mosquito protection night / sleeping 166 (75.5) 23 (69.7) 143 (76.5) 0.41 
 
